Literature DB >> 11861850

Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction.

Christophe Guillon1, Martin Schutten, Patrick H M Boers, Rob A Gruters, Albert D M E Osterhaus.   

Abstract

In this study, we characterized the viral determinants of coreceptor usage in relation to susceptibility to antibody-mediated neutralization or enhancement of infectivity by using chimeras of three highly related human immunodeficiency virus type 1 (HIV-1) isolates of different phenotypes. We found that the V3 region was the main determinant of antibody-mediated enhancement and coreceptor specificity but that the overall structure of gp120 was also important for these properties. Constructs susceptible to antibody-mediated enhancement preferentially use CCR5 as a coreceptor, in contrast to constructs that were neutralized or not affected. Using monoclonal antibodies directed against CD4 or CCR5, we were able to show that antibody-mediated enhancement was CD4 dependent. Altogether, our results suggest that the modulation of the interaction of gp120 with CCR5 is the mechanism underlying antibody-mediated enhancement of HIV-1 infectivity.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11861850      PMCID： PMC135957          DOI： 10.1128/jvi.76.6.2827-2834.2002

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  56 in total

1.  Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.

Authors:  A Björndal; H Deng; M Jansson; J R Fiore; C Colognesi; A Karlsson; J Albert; G Scarlatti; D R Littman; E M Fenyö
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Modulation of primary human immunodeficiency virus type 1 envelope glycoprotein-mediated entry by human antibodies.

Authors:  M Schutten; A C Andeweg; G F Rimmelzwaan; A D Osterhaus
Journal:  J Gen Virol       Date:  1997-05       Impact factor: 3.891

3.  Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32.

Authors:  M Benkirane; D Y Jin; R F Chun; R A Koup; K T Jeang
Journal:  J Biol Chem       Date:  1997-12-05       Impact factor: 5.157

4.  The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity.

Authors:  A Trkola; C Gordon; J Matthews; E Maxwell; T Ketas; L Czaplewski; A E Proudfoot; J P Moore
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.

Authors:  C M Hill; H Deng; D Unutmaz; V N Kewalramani; L Bastiani; M K Gorny; S Zolla-Pazner; D R Littman
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

6.  CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry.

Authors:  J D Reeves; A McKnight; S Potempa; G Simmons; P W Gray; C A Power; T Wells; R A Weiss; S J Talbot
Journal:  Virology       Date:  1997-04-28       Impact factor: 3.616

7.  Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage.

Authors:  D C Montefiori; R G Collman; T R Fouts; J Y Zhou; M Bilska; J A Hoxie; J P Moore; D P Bolognesi
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.

Authors:  A Trkola; T Ketas; V N Kewalramani; F Endorf; J M Binley; H Katinger; J Robinson; D R Littman; J P Moore
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding.

Authors:  L Wu; G LaRosa; N Kassam; C J Gordon; H Heath; N Ruffing; H Chen; J Humblias; M Samson; M Parmentier; J P Moore; C R Mackay
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

10.  Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization.

Authors:  S Ugolini; I Mondor; P W Parren; D R Burton; S A Tilley; P J Klasse; Q J Sattentau
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307
View more
  11 in total

1.  Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Authors:  Evgeny Shmelkov; Arthur Nadas; Timothy Cardozo
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

2.  Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251.

Authors:  Johannes S Gach; David Venzon; Monica Vaccari; Brandon F Keele; Genoveffa Franchini; Donald N Forthal
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

3.  Enhancement of HIV infection by cellulose sulfate.

Authors:  Wang Tao; Chris Richards; Dean Hamer
Journal:  AIDS Res Hum Retroviruses       Date:  2008-07       Impact factor: 2.205

4.  Fc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells.

Authors:  Ramil Sapinoro; Ketna Volcy; W W Shanaka I Rodrigo; Jacob J Schlesinger; Stephen Dewhurst
Journal:  Virology       Date:  2008-01-14       Impact factor: 3.616

5.  Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope.

Authors:  Zhi-yong Yang; Bimal K Chakrabarti; Ling Xu; Brent Welcher; Wing-pui Kong; Kwanyee Leung; Amos Panet; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 6.  Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

7.  The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.

Authors:  Sandeep Gupta; Johannes S Gach; Juan C Becerra; Tran B Phan; Jeffrey Pudney; Zina Moldoveanu; Sarah B Joseph; Gary Landucci; Medalyn Jude Supnet; Li-Hua Ping; Davide Corti; Brian Moldt; Zdenek Hel; Antonio Lanzavecchia; Ruth M Ruprecht; Dennis R Burton; Jiri Mestecky; Deborah J Anderson; Donald N Forthal
Journal:  PLoS Pathog       Date:  2013-11-21       Impact factor: 6.823

Review 8.  The Comparative Value of Feline Virology Research: Can Findings from the Feline Lentiviral Vaccine Be Translated to Humans?

Authors:  Margaret J Hosie; Navapon Techakriengkrai; Paweł M Bęczkowski; Matthew Harris; Nicola Logan; Brian J Willett
Journal:  Vet Sci       Date:  2017-01-28

Review 9.  Vaccine-induced enhancement of viral infections.

Authors:  W Huisman; B E E Martina; G F Rimmelzwaan; R A Gruters; A D M E Osterhaus
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

10.  Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates.

Authors:  Qidi Wang; Lianfeng Zhang; Kazuhiko Kuwahara; Li Li; Zijie Liu; Taisheng Li; Hua Zhu; Jiangning Liu; Yanfeng Xu; Jing Xie; Hiroshi Morioka; Nobuo Sakaguchi; Chuan Qin; Gang Liu
Journal:  ACS Infect Dis       Date:  2016-04-11       Impact factor: 5.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.